Lonza vs Northway Biotech: CDMO Comparison
How does Lonza compare to Northway Biotech for AAV manufacturing?
Side-by-side comparison of Lonza and Northway Biotech on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Lonza has FDA inspections on record (2); Northway Biotech does not yet appear in the FDA inspection database.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Northway Biotech has materially broader EMA GMP coverage (8 active certificates vs 3) — stronger EU footprint.
- Lonza maintains 5 MHRA / UK GMP certificates; Northway Biotech does not.
On a 13-modality CDMO landscape, both Lonza and Northway Biotech qualify as AAV manufacturers; Northway Biotech carries the higher composite Signal Score for AAV programs in this comparison.
What to evaluate for AAV programs
Both Lonza and Northway Biotech qualify as AAV CDMOs. When choosing between them for AAV programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Platform & scale
Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record.
Capsid quality
Full/empty capsid ratio and aggregate control drive potency and safety. Ask about AUC, anion-exchange separation, and the analytics package for capsid characterization.
Regulatory readiness
For programs heading to BLA, a strong FDA inspection history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.
Capacity & timelines
AAV manufacturing slots can be constrained. Weigh the capacity signal and clinical-program load before committing.
Frequently asked: Lonza vs Northway Biotech
How does Lonza compare to Northway Biotech for AAV manufacturing?
On CDMO Signal's composite Signal Score, Lonza is 78/100 and Northway Biotech is 81/100; Lonza has 2 FDA inspections on record vs 0 for Northway Biotech; European coverage is 8 active EMA+MHRA certificates for Lonza vs 8 for Northway Biotech. Both are tracked in the CDMO Signal directory as AAV CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Lonza or Northway Biotech?
Both Lonza and Northway Biotech maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Lonza has 2 FDA inspections on record; Northway Biotech has 0.
How do Lonza and Northway Biotech compare on European GMP coverage?
Lonza holds 3 active EMA GMP certificates and 5 MHRA / UK certificates. Northway Biotech holds 8 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — Lonza or Northway Biotech?
Lonza is matched to 1 ClinicalTrials.gov record as a manufacturing partner; Northway Biotech is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for AAV manufacturing — Lonza or Northway Biotech?
Both Lonza and Northway Biotech are tagged as AAV CDMOs in our directory, so both are credible options for AAV programs. The most important differentiator for AAV selection is typically platform & scale: Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record. Review each CDMO's profile and inspection record before shortlisting.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →